# Population Pharmacokinetics of Teicoplanin, Levofloxacin, Piperacillin/Tazobactam, Meropenem, Vancomycin, Remifentanil, Cefepime, Cefpirome, Sufentanil, Midazolam, Clopidogrel, Ticagrelor, Prasugrel During Veno-arterial Extracorporeal Membrane Oxygenation (VA ECMO)

> **NCT02581280** · — · COMPLETED · sponsor: **Yonsei University** · enrollment: 56 (actual)

## Conditions studied

- Cardiac Dysfunction

## Interventions

- **OTHER:** Residual blood

## Key facts

- **NCT ID:** NCT02581280
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2019-01-31
- **Final completion:** 2019-01-31
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2019-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02581280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02581280, "Population Pharmacokinetics of Teicoplanin, Levofloxacin, Piperacillin/Tazobactam, Meropenem, Vancomycin, Remifentanil, Cefepime, Cefpirome, Sufentanil, Midazolam, Clopidogrel, Ticagrelor, Prasugrel During Veno-arterial Extracorporeal Membrane Oxygenation (VA ECMO)". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT02581280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*